Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06480605 phase 2a study in moderate to severe ulcerative colitis
NL-OMON47159Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afimkibart in autoimmune colitis, sponsored by Pfizer. Primary endpoints: Safety and tolerability and Endoscopic improvement at Week 14. Started Oct 2017; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47159.